Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Bipolar Disorder Clinical Trials

A listing of Bipolar Disorder medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (35) clinical trials

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-007 MONOTHERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION)

Phase

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-007 ADJUNCTIVE TO LITHIUM OR VALPROATE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION)

Phase

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIXED-DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I DEPRESSION

Phase

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, MULTICENTER, FIXED-DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I DEPRESSION

Phase

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-007 MONOTHERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION)

Phase

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-007 ADJUNCTIVE TO LITHIUM OR VALPROATE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION)

Phase

The purpose of this study is to measure the efficacy of fixed dose treatments of cariprazine for the treatment of bipolar depression.

Phase

This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder.

Phase

A phase III Efficacy and Safety of 3 week fixed dose asenapin treatment in pediatric acute manic or mixed episodes associated with Bipolar 1 Disorder in adolescents. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from bipolar 1 disorder.

Phase